Castle Biosciences, Inc. (CSTL) jumped 19.06% to $30.94, up $4.95, following the release of its third-quarter 2025 financial results.
The company reported revenue of $83.0 million, and announced it is raising its full-year 2025 revenue guidance to $327-335 million, up from the prior range of $310-320 million.
Management noted that core revenue drivers, DecisionDx-Melanoma and TissueCypher, delivered strong volume growth (test reports up 36 percent year-over-year) despite headwinds from coverage changes.
On the day of the announcement, CSTL opened near $26.00, reached highs around $31.00, and closed at $30.94, with trading volume markedly above its average. The stock's 52-week range is approximately $14.59 - $35.84.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.